Raheleh Amirkhah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Raheleh Amirkhah has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
- Philip David Dunne
Queens University Belfast, Patrick G Johnston Centre for Cancer Research, Belfast, UK
50 shared publications Keara L. Redmond
34 shared publications- Sudhir B. Malla
Queen's University Belfast
34 shared publications - Enric Domingo
University of Oxford
32 shared publications - Viktor Hendrik Koelzer
University Hospital Basel
32 shared publications - Natalie C. Fisher
The Patrick G Johnston Centre for Cancer Research, Queen’s University Belfast, Belfast, UK
31 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (10) , 1705-1714
Immune and stromal tumour biology associated with neoadjuvant radiotherapy response in locally advanced rectal cancer
Background: Response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer (LARC) is heterogeneous. The Neoadjuvant Rectal (NAR) score quantifies treatment response via tumour downstaging and nodal status and correlates with survival outcomes. This work set out to explore whether low NAR and high NAR tumours represent biologically distinct groups pre-treatment. Methods: Transcriptome microarrays quantified RNA expression within pre-treatment biopsies from LARC patients in GSE87211 and S:CORT consortium Grampian datasets. A validation cohort from the Beatson West of Scotland Cancer Centre was analysed using multiplex immunofluorescence and H&E-derived tumour-stromal ratios. Results: Seventeen MSigDB Hallmarks were enriched in high NAR tumours; ‘Epithelial-Mesenchymal Transition’ was notably enriched (padj < 0.001). Immune-related signatures were enriched in low NAR tumours ( p < 0.25). Both cohorts showed higher Microenvironment Cell Population counter ‘Cytotoxic Lymphocytes’ in low NAR ( p < 0.05) and more stromal cells (‘Endothelial Cells’, ‘Fibroblasts’; p < 0.05) in high NAR tumours. CD8 densities confirmed higher immune infiltration in low NAR tumours. Discussion: Pre-treatment biopsies show consistent microenvironmental differences between high and low NAR tumours. While immune and stromal features are associated with response, the observed differences are insufficient to serve as standalone predictive biomarkers.
- 18 August 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (10) , 1705-1714
Open AccessImmune and stromal tumour biology associated with neoadjuvant radiotherapy response in locally advanced rectal cancer
Background: Response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer (LARC) is heterogeneous. The Neoadjuvant Rectal (NAR) score quantifies treatment response via tumour downstaging and nodal status and correlates with survival outcomes. This work set out to explore whether low NAR and high NAR tumours represent biologically distinct groups pre-treatment. Methods: Transcriptome microarrays quantified RNA expression within pre-treatment biopsies from LARC patients in GSE87211 and S:CORT consortium Grampian datasets. A validation cohort from the Beatson West of Scotland Cancer Centre was analysed using multiplex immunofluorescence and H&E-derived tumour-stromal ratios. Results: Seventeen MSigDB Hallmarks were enriched in high NAR tumours; ‘Epithelial-Mesenchymal Transition’ was notably enriched (padj < 0.001). Immune-related signatures were enriched in low NAR tumours ( p < 0.25). Both cohorts showed higher Microenvironment Cell Population counter ‘Cytotoxic Lymphocytes’ in low NAR ( p < 0.05) and more stromal cells (‘Endothelial Cells’, ‘Fibroblasts’; p < 0.05) in high NAR tumours. CD8 densities confirmed higher immune infiltration in low NAR tumours. Discussion: Pre-treatment biopsies show consistent microenvironmental differences between high and low NAR tumours. While immune and stromal features are associated with response, the observed differences are insufficient to serve as standalone predictive biomarkers.
- Open Access
- 23 June 2026
- Published by Springer Nature in Research Square
Stromal Prostaglandin is a Dominant Spatial Regulator of Cell-fate Plasticity in Colorectal Cancer
Colorectal cancer (CRC) tumours with high stromal content have a worse outcome, but the mechanisms governing this are unclear. Using high-throughput single-cell perturbation analysis of CRC patient-derived organoids (PDOs) and cancer-associated fibroblasts (CAFs) we find that epithelial cells with high stromal-communication potential are marked by the transcriptional co-repressor DACH1 . To define the causal regulators of stromal-epithelial signalling, we developed a novel CRISPR screening platform to perturb the CAF secretome and measure epithelial stem cell responses at single-cell resolution. Intercellular CRISPR screening and full factorial ligand analysis revealed that stromal Prostaglandin E2 (PGE 2 ) is a dominant regulator of CRC cell-fate plasticity. Stromal PGE 2 converts DACH1 + epithelia from a chemosensitive proliferative colonic stem cell (proCSC) fate into a chemorefractory and pro-metastatic revival colonic stem cell (revCSC) fate. PGE 2 -driven epithelial transdetermination is rapid and reversible, providing an acute mechanism for stromal-driven plasticity in CRC tumours. Genetic and pharmacological inhibition of stromal COX2 inhibits epithelial plasticity, trapping CRC epithelia in an anti-metastatic and chemosensitive proCSC fate. PTGS2 + CAFs support a spatially resolved revCSC to proCSC plasticity gradient in human CRC tumours marked by increasing DACH1 expression. These results reveal that stromal prostaglandin is a dominant spatial regulator of poor-prognosis cell-fates and may explain the benefit of anti-COX therapies in both preventing and treating CRC.
- 23 June 2026
- Published by Springer Nature in Research Square
Open AccessStromal Prostaglandin is a Dominant Spatial Regulator of Cell-fate Plasticity in Colorectal Cancer
Colorectal cancer (CRC) tumours with high stromal content have a worse outcome, but the mechanisms governing this are unclear. Using high-throughput single-cell perturbation analysis of CRC patient-derived organoids (PDOs) and cancer-associated fibroblasts (CAFs) we find that epithelial cells with high stromal-communication potential are marked by the transcriptional co-repressor DACH1 . To define the causal regulators of stromal-epithelial signalling, we developed a novel CRISPR screening platform to perturb the CAF secretome and measure epithelial stem cell responses at single-cell resolution. Intercellular CRISPR screening and full factorial ligand analysis revealed that stromal Prostaglandin E2 (PGE 2 ) is a dominant regulator of CRC cell-fate plasticity. Stromal PGE 2 converts DACH1 + epithelia from a chemosensitive proliferative colonic stem cell (proCSC) fate into a chemorefractory and pro-metastatic revival colonic stem cell (revCSC) fate. PGE 2 -driven epithelial transdetermination is rapid and reversible, providing an acute mechanism for stromal-driven plasticity in CRC tumours. Genetic and pharmacological inhibition of stromal COX2 inhibits epithelial plasticity, trapping CRC epithelia in an anti-metastatic and chemosensitive proCSC fate. PTGS2 + CAFs support a spatially resolved revCSC to proCSC plasticity gradient in human CRC tumours marked by increasing DACH1 expression. These results reveal that stromal prostaglandin is a dominant spatial regulator of poor-prognosis cell-fates and may explain the benefit of anti-COX therapies in both preventing and treating CRC.
- Open Access
Stromal Prostaglandin is a Dominant Spatial Regulator of Cell-fate Plasticity in Colorectal Cancer
Colorectal cancer (CRC) tumours with high stromal content have a worse outcome, but the mechanisms governing this are unclear. Using high-throughput single-cell perturbation analysis of CRC patient-derived organoids (PDOs) and cancer-associated fibroblasts (CAFs) we find that epithelial cells with high stromal-communication potential are marked by the transcriptional co-repressor DACH1 . To define the causal regulators of stromal-epithelial signalling, we developed a novel CRISPR screening platform to perturb the CAF secretome and measure epithelial stem cell responses at single-cell resolution. Intercellular CRISPR screening and full factorial ligand analysis revealed that stromal Prostaglandin E2 (PGE 2 ) is a dominant regulator of CRC cell-fate plasticity. Stromal PGE 2 converts DACH1 + epithelia from a chemosensitive proliferative colonic stem cell (proCSC) fate into a chemorefractory and pro-metastatic revival colonic stem cell (revCSC) fate. PGE 2 -driven epithelial transdetermination is rapid and reversible, providing an acute mechanism for stromal-driven plasticity in CRC tumours. Genetic and pharmacological inhibition of stromal COX2 inhibits epithelial plasticity, trapping CRC epithelia in an anti-metastatic and chemosensitive proCSC fate. PTGS2 + CAFs support a spatially resolved revCSC to proCSC plasticity gradient in human CRC tumours marked by increasing DACH1 expression. These results reveal that stromal prostaglandin is a dominant spatial regulator of poor-prognosis cell-fates and may explain the benefit of anti-COX therapies in both preventing and treating CRC.
Open AccessStromal Prostaglandin is a Dominant Spatial Regulator of Cell-fate Plasticity in Colorectal Cancer
Colorectal cancer (CRC) tumours with high stromal content have a worse outcome, but the mechanisms governing this are unclear. Using high-throughput single-cell perturbation analysis of CRC patient-derived organoids (PDOs) and cancer-associated fibroblasts (CAFs) we find that epithelial cells with high stromal-communication potential are marked by the transcriptional co-repressor DACH1 . To define the causal regulators of stromal-epithelial signalling, we developed a novel CRISPR screening platform to perturb the CAF secretome and measure epithelial stem cell responses at single-cell resolution. Intercellular CRISPR screening and full factorial ligand analysis revealed that stromal Prostaglandin E2 (PGE 2 ) is a dominant regulator of CRC cell-fate plasticity. Stromal PGE 2 converts DACH1 + epithelia from a chemosensitive proliferative colonic stem cell (proCSC) fate into a chemorefractory and pro-metastatic revival colonic stem cell (revCSC) fate. PGE 2 -driven epithelial transdetermination is rapid and reversible, providing an acute mechanism for stromal-driven plasticity in CRC tumours. Genetic and pharmacological inhibition of stromal COX2 inhibits epithelial plasticity, trapping CRC epithelia in an anti-metastatic and chemosensitive proCSC fate. PTGS2 + CAFs support a spatially resolved revCSC to proCSC plasticity gradient in human CRC tumours marked by increasing DACH1 expression. These results reveal that stromal prostaglandin is a dominant spatial regulator of poor-prognosis cell-fates and may explain the benefit of anti-COX therapies in both preventing and treating CRC.
- Open Access
- 26 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Viral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state
In colorectal cancer (CRC), tumours classified as consensus molecular subtype 4 (CMS4) have the worst prognosis and derive negligible benefit from chemotherapy. We previously described how repressed interferon-related signalling is associated with increased relapse in CMS4 tumours. Although the viral mimetic polyinosinic:polycytidylic acid, poly(I:C), can reduce liver metastasis in vivo, the initial phenotypic changes that underpin its anti-metastatic response remain poorly described, particularly in the immunosuppressed CMS4 tumour microenvironment. Here we characterise lineage-specific anti-metastatic responses induced by poly(I:C), including acute macrophage polarisation and a novel CMS1-like regenerative stem cell state, which drive pro-inflammatory microenvironmental changes in CRC. These insights enabled the development of tractable biomarkers that identify an “immune-warm” patient subset most likely to respond to poly(I:C), enriched for mismatch-repair proficient (pMMR), anti-inflammatory macrophages and CMS4-like features. The viral mimetic poly(I:C) offers a tailored treatment option for poor-prognostic tumours, by reprogramming stem cell states and activation of an innate-adaptive anti-metastatic response.
- 26 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessViral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state
In colorectal cancer (CRC), tumours classified as consensus molecular subtype 4 (CMS4) have the worst prognosis and derive negligible benefit from chemotherapy. We previously described how repressed interferon-related signalling is associated with increased relapse in CMS4 tumours. Although the viral mimetic polyinosinic:polycytidylic acid, poly(I:C), can reduce liver metastasis in vivo, the initial phenotypic changes that underpin its anti-metastatic response remain poorly described, particularly in the immunosuppressed CMS4 tumour microenvironment. Here we characterise lineage-specific anti-metastatic responses induced by poly(I:C), including acute macrophage polarisation and a novel CMS1-like regenerative stem cell state, which drive pro-inflammatory microenvironmental changes in CRC. These insights enabled the development of tractable biomarkers that identify an “immune-warm” patient subset most likely to respond to poly(I:C), enriched for mismatch-repair proficient (pMMR), anti-inflammatory macrophages and CMS4-like features. The viral mimetic poly(I:C) offers a tailored treatment option for poor-prognostic tumours, by reprogramming stem cell states and activation of an innate-adaptive anti-metastatic response.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Average C-reactive protein at each timepoint, in each treatment group
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Average C-reactive protein at each timepoint, in each treatment group
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Concentrations of cytokines in peripheral blood
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Concentrations of cytokines in peripheral blood
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Individual patient microenvironment cell population counter scores
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Individual patient microenvironment cell population counter scores
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Analytes for Bioteche 25-plex Immunopathology Multiplex Cytokine Assay
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Analytes for Bioteche 25-plex Immunopathology Multiplex Cytokine Assay
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Drug names and dosing schedules
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Drug names and dosing schedules
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Waterfall plots representing change in lymphocyte concentrations.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
Waterfall plots representing change in lymphocyte concentrations.